STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy
Wang-Bishop L, Kimmel B, Ngwa V, Madden M, Baljon J, Florian D, Hanna A, Pastora L, Sheehy T, Kwiatkowski A, Wehbe M, Wen X, Becker K, Garland K, Schulman J, Shae D, Edwards D, Wolf M, Delapp R, Christov P, Beckermann K, Balko J, Rathmell W, Rathmell J, Chen J, Wilson J. STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy. Science Immunology 2023, 8: eadd1153. PMID: 37146128, PMCID: PMC10226150, DOI: 10.1126/sciimmunol.add1153.Peer-Reviewed Original ResearchConceptsSTING-activating nanoparticlesT cell infiltrationCell infiltrationT cellsAdoptive T-cell therapyMultiple mouse tumor modelsT-cell adhesion moleculesImmune checkpoint inhibitorsEffector T cellsAntitumor T cellsT-cell therapyEffective tumor controlCyclic dinucleotide STING agonistsEndothelial cell expressionTumor-associated vasculatureMouse tumor modelsCheckpoint inhibitorsCancer immunotherapyTumor controlVascular normalizationIntravenous administrationCell adhesion moleculeAntitumor functionSTING agonistsCell expression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply